TrialCPT: pharmacometrics & systems pharmacology2020

Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain.

Mita Kuchimanchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.